A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer
暂无分享,去创建一个
Jordan F Hastings | David R. Croucher | J. Kench | L. Andrews | R. Hruban | J. Eshleman | A. Biankin | M. Pajic | N. Waddell | S. Grimmond | R. Pidsley | N. Pavlakis | S. Clark | J. Kirk | A. Scarpa | P. Timpson | A. Patch | A. Johns | K. Nones | O. Holmes | S. Kazakoff | C. Leonard | F. Newell | S. Wood | A. Nagrial | L. Chantrill | A. Steinmann | A. Chou | J. Samra | K. Epari | A. Barbour | N. Zeps | N. Jamieson | elliot k fishman | R. Lawlor | V. Corbo | C. Bassi | A. Gill | R. S. Mead | P. Grimison | R. Asghari | M. Lucas | K. Murphy | D. Herrmann | P. Phillips | Alice G. Russo | A. Ruszkiewicz | M. Texler | C. Sandroussi | C. Vennin | W. Jarolimek | P. Mukhopadhyay | A. Clouston | L. Perryman | P. Cosman | V. Addala | Sharissa L. Latham | M. Nikfarjam | Andrew M. Da Silva | M. Papanicolaou | A. Stoita | S. Dreyer | A. Findlay | Katherine Tucker | Amelia L. Parker | Elysse C Filipe | Brooke A. Pereira | Joanna N Skhinas | A. Goodwin | M. Yam | M. Brooke-Smith | G. Sharbeen | Gretel S Major | K. Feeney | Jessica L. Chitty | K. Slater | John Chen | Joanna N. Skhinas | Thomas R. Cox | Rhiannon Grant | Ellie Mok | J. Arena | Peter Hodgkinson | D. Fletcher | Victoria Lee | M. Hatzifotis | M. Arshi | H. High | J. Youkhana | V. Papangelis | K. Ismail | Amitabha Das | Kaitlin Wyllie | Emmi Tran | A. Nadalini | A. Zaratzian | Michael Trpceski | Oliver Hofmann | Shona Ritchie | Pauline Mélénec | M. Beilin | N. Merrett | M. Nobis | Tanya M. Dwarte | Michael Tayao | Yordanos F I Setargew | M. Ballal | Xanthe L Metcalf | David B. Williams | Allan Spigellman | Sanjay Mukhedkar | Nan Q. Nguyen | C. Worthley | T. J. O'Rourke | John V. Pearson | G. Jeong | Daniel A. Reed | T. Schmitz | Janett Stoehr | Lea Abdulkhalek | Cindy Forrest | C. Chambers | Kym Pham Stewart | D. Chang | Bret Charlton | Sipiththa Velayuthar | Shivanjali Ratnaseelan | Antonia Blackwell | Lara Kenyon | Duncan McLeo | J. W. Fawcett | Kellee Slater | Gretel S. Major | Anaiis Zaratzian | T. Cox
[1] K. Ask,et al. Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis , 2021, International journal of molecular sciences.
[2] N. Merchant,et al. Targeting Tumor–Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer , 2021, Molecular Cancer Therapeutics.
[3] K. Pietras,et al. CCM3 is a gatekeeper in focal adhesions regulating mechanotransduction and YAP/TAZ signalling , 2021, Nature Cell Biology.
[4] T. Cox. The matrix in cancer , 2021, Nature Reviews Cancer.
[5] Wei Zhang,et al. IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway. , 2020, Cancer letters.
[6] S. Connor,et al. Pathological assessment of tumour regression following neoadjuvant therapy in pancreatic carcinoma. , 2020, Pathology.
[7] Keith E. Volmar,et al. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. , 2020, The Journal of clinical investigation.
[8] V. Gebski,et al. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition , 2020, Cancer Research.
[9] D. Tuveson,et al. DIVERSITY AND BIOLOGY OF CANCER-ASSOCIATED FIBROBLASTS. , 2020, Physiological reviews.
[10] V. Weaver,et al. The fibrotic tumor stroma. , 2020, Biochimica et biophysica acta. Reviews on cancer.
[11] I. Romero‐Canelón,et al. Lysyl Oxidase Like‐2 (LOXL2): An Emerging Oncology Target , 2020 .
[12] Thea D. Tlsty,et al. A framework for advancing our understanding of cancer-associated fibroblasts , 2020, Nature Reviews Cancer.
[13] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[14] T. Cox,et al. Targeting the lysyl oxidases in tumour desmoplasia. , 2019, Biochemical Society transactions.
[15] P. Timpson,et al. CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer. , 2019, Trends in cancer.
[16] H. Schilter,et al. Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-Like 2/3. , 2019, Journal of medicinal chemistry.
[17] David R. Croucher,et al. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan , 2019, Nature Communications.
[18] P. Timpson,et al. The Mini‐Organo: A rapid high‐throughput 3D coculture organotypic assay for oncology screening and drug development , 2019, Cancer reports.
[19] D. Tuveson,et al. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? , 2018, Gut.
[20] K. Harikumar,et al. Targeting S1PR1/STAT3 loop abrogates desmoplasia and chemosensitizes pancreatic cancer to gemcitabine , 2018, Theranostics.
[21] M. Pajic,et al. Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer. , 2017, Gastroenterology.
[22] M. Pajic,et al. Three-dimensional organotypic matrices from alternative collagen sources as pre-clinical models for cell biology , 2017, Scientific Reports.
[23] J. Windsor,et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. , 2017, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[24] Xiaoqing Pan,et al. IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma , 2017, Molecular Cancer Therapeutics.
[25] J. Erler,et al. ISDoT: in situ decellularization of tissues for high-resolution imaging and proteomic analysis of native extracellular matrix , 2017, Nature Medicine.
[26] Max Nobis,et al. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis , 2017, Science Translational Medicine.
[27] J. Bendell,et al. A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second‐Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma , 2017, The oncologist.
[28] Z. Wainberg,et al. A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma , 2017, The oncologist.
[29] Wolfgang,et al. Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer , 2017, Oncotarget.
[30] J. Freeman,et al. Downregulation of STAT3/NF‐κB potentiates gemcitabine activity in pancreatic cancer cells , 2017, Molecular carcinogenesis.
[31] Peter Bankhead,et al. QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.
[32] D. Tuveson,et al. Corrigendum: Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis , 2016, Nature Cell Biology.
[33] J. Erler,et al. Fibrosis and Cancer: Partners in Crime or Opposing Forces? , 2016, Trends in cancer.
[34] P. Dubus,et al. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution , 2016, Oncotarget.
[35] O. Sansom,et al. GEMMs as preclinical models for testing pancreatic cancer therapies , 2015, Disease Models & Mechanisms.
[36] Karin Oien,et al. Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy , 2015, EMBO molecular medicine.
[37] D. Tuveson,et al. Stromal biology and therapy in pancreatic cancer: a changing paradigm , 2015, Gut.
[38] J. Kench,et al. Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.
[39] Daniel S. Puperi,et al. Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma. , 2015, The Journal of clinical investigation.
[40] L. Chin,et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. , 2014, Cancer Cell.
[41] Stephen A. Sastra,et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. , 2014, Cancer cell.
[42] Benjamin D. Smith,et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.
[43] J. Erler,et al. Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK , 2013, Oncogene.
[44] J. Erler,et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. , 2013, Cancer research.
[45] Lincoln D. Stein,et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.
[46] Thomas R. Cox,et al. The rationale for targeting the LOX family in cancer , 2012, Nature Reviews Cancer.
[47] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[48] Thomas R Cox,et al. The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer. , 2011, Journal of the National Cancer Institute.
[49] C. Wai,et al. Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment , 2010, Nature Medicine.
[50] Jennifer P Morton,et al. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. , 2010, Gastroenterology.
[51] David M. Rissin,et al. Single-Molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations , 2010, Nature Biotechnology.
[52] Paul Timpson,et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer , 2010, Proceedings of the National Academy of Sciences.
[53] J. Erler,et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. , 2009, Cancer cell.
[54] David Goldstein,et al. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. , 2008, Cancer research.
[55] M. Palcic,et al. A peroxidase-coupled continuous absorbance plate-reader assay for flavin monoamine oxidases, copper-containing amine oxidases and related enzymes , 2006, Nature Protocols.
[56] R. Hruban,et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.
[57] A. Sjoerdsma,et al. Studies on beta‐aminopropionitrile in patients with scleroderma , 1967, Clinical pharmacology and therapeutics.
[58] Amna Zahoor,et al. Measurement of Collagen Cross-Links from Tissue Samples by Mass Spectrometry. , 2019, Methods in molecular biology.
[59] P. Trackman,et al. Measurement of lysyl oxidase activity from small tissue samples and cell cultures. , 2018, Methods in cell biology.
[60] H. Collard,et al. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. , 2017, The Lancet. Respiratory medicine.